Efficacy of prophylactic levofloxacin in cancer patients with neutropenia
Tamsin Osborne
This article has no abstract so we have provided the first paragraph of the full text.
A prospective, multicenter, double-blind, randomized, placebo-controlled trial provides compelling evidence of the benefits of levofloxacin prophylaxis in cancer patients with chemotherapy-induced neutropenia. Despite the fact that these patients frequently develop life-threatening bacterial infections, the prophylactic use of fluoroquinolones to prevent this remains controversial.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Mycobacterium tuberculosis virulence: lipids inside and outNature Medicine News and Views (01 Mar 2007)